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RadiotherapyBackground and purpose: A rapid learning approach has been proposed to extract and apply knowledge
from routine care data rather than solely relying on clinical trial evidence. To validate this in practice
we deployed a previously developed decision support system (DSS) in a typical, busy clinic for non-small
cell lung cancer (NSCLC) patients.
Material and methods: Gender, age, performance status, lung function, lymph node status, tumor volume
and survival were extracted without review from clinical data sources for lung cancer patients. With
these data the DSS was tested to predict overall survival.
Results: 3919 lung cancer patients were identiﬁed with 159 eligible for inclusion, due to ineligible histol-
ogy or stage, non-radical dose, missing tumor volume or survival. The DSS successfully identiﬁed a good
prognosis group and a medium/poor prognosis group (2 year OS 69% vs. 27/30%, p < 0.001). Stage was less
discriminatory (2 year OS 47% for stage I–II vs. 36% for stage IIIA–IIIB, p = 0.12) with most good prognosis
patients having higher stage disease. The DSS predicted a large absolute overall survival beneﬁt (40%)
for a radical dose compared to a non-radical dose in patients with a good prognosis, while no survival
beneﬁt of radical radiotherapy was predicted for patients with a poor prognosis.
Conclusions: A rapid learning environment is possible with the quality of clinical data sufﬁcient to vali-
date a DSS. It uses patient and tumor features to identify prognostic groups in whom therapy can be indi-
vidualized based on predicted outcomes. Especially the survival beneﬁt of a radical versus non-radical
dose predicted by the DSS for various prognostic groups has clinical relevance, but needs to be prospec-
tively validated.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 47–53 This
is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/
3.0/).Lung cancer has a global incidence of 1.6 million with 1.4
million lung cancer deaths per year [1]. In the developed world,
85% of cases are non-small cell lung cancer (NSCLC) patients and
44% present with non-metastatic disease, for whom primary radi-
cal surgery or radiotherapy, in combination with chemotherapy, is
indicated [2]. The outcome of inoperable NSCLC undergoing radical
(chemo)radiotherapy is bleak with two-year overall survival
(2 year-OS) rates reported as approximately 50% in early stage
(stage I–II) patients [3] and 25% in locally advanced cancers (stage
IIIA–IIIB) [4]. To improve survival, more individualized radiother-
apy schedules have been proposed with encouraging results [5].To inform decision making and enable individualized therapy a
validated prediction of expected outcome is needed for an individ-
ual patient. This can be provided via clinical decision support sys-
tems (DSS) [6]. A rapid learning health-care system, where we can
learn from each patient to guide practice, has been proposed to
extract knowledge, such as a DSS, from routine clinical care data
rather than solely relying on evidence from clinical trials [7,8].
Previous rapid learning work has resulted in a DSS (www.predict-
cancer.org) which can predict overall survival in non-small cell
lung cancer patients treated with radical (chemo) radiotherapy
[9]. This DSS might be used in a clinic as an objective guide to indi-
vidualize treatment, and discussions with patients, according to
prognosis.
To validate a DSS, input features and outcome data from the
local care population (called the clinical cohort in this report)
are needed. However capturing and extracting data requires
48 Rapid learning in practicesigniﬁcant resources, which limits the acceptance of DSSs and
rapid learning in general. If successfully extracted, such new data
cannot only be used for validation but also to identify improve-
ments and to assess clinical relevance by investigating if and
how the DSS might change local practice.
In this study, we hypothesize that it is possible to deploy a rapid
learning environment which can be used to validate the above DSS.
Our aim is to apply rapid learning in practice, to see if this novel
approach is feasible in a typical, busy cancer center, to test the lim-
its and areas of improvement and to determine the clinical rele-
vance of the DSS.Materials and methods
Patients
All lung cancer patients in whom electronic routine care data
were available at Liverpool and Macarthur Cancer Therapy Centres,
Sydney, Australia were selected for consideration for the clinical
cohort. This is an integrated cancer center which multi-disciplinary
treats approximately 2000 patients per year with radiotherapy and
records data in an oncology information system (MOSAIQ, Elekta,
Stockholm, Sweden). A previously published [9] DSS was learned
from a cohort consisting of 322 consecutive lung cancer patients
from MAASTRO Clinic, The Netherlands using 2-norm support vec-
tor machines, using two year overall survival, calculated from the
start of the RT, as the outcome measure. This cohort is called the
training cohort in this report. The study was approved by the inter-
nal ethics review boards of both institutes.
To match the clinical cohort to the training cohort the following
inclusion and exclusion criteria were applied. Inclusion: non-small
cell lung cancer; stage I–IIIB; prescribed radiation dose 4500 cGy or
higher with at least one fraction of radiotherapy administered.
Exclusion: small cell lung cancer, stage IV, prescribed radiation less
than 4500 cGy. Two additional criteria were applied to the clinical
cohort: no missing data for the outcome feature (2 year-OS) and
the tumor volume (the sum of local and regional gross tumor vol-
ume in cubic centimeters). The ﬁrst is needed to validate the DSS,
the second is the most sensitive feature of the DSS for which impu-
tation was deemed too unreliable. Missing data were allowed for
the other DSS input features being gender, ECOG performance sta-
tus, forced expiratory volume in 1 s (FEV1), number of positive
lymph node stations on a PET scan (PLNS); these were imputed
before validation (see below).Data sources and extraction of the clinical cohort
The oncology information system and treatment planning sys-
tem (XiO, Elekta, Stockholm, Sweden) were used as the data sources
for the clinical cohort. From the treatment planning system a cus-
tom bulk export script was used to extract all CT-delineated struc-
tures and their volume as DICOM objects which were stored in an
open source java-based PACS (DCM4CHEE) [10]. An open source
java-based data integration platform (Kettle, Pentaho, Orlando, FL,
USA) was used to extract and store the relevant features as state-
ments on patients in the form of triples (e.g., Patient1-hasGender-
Male) to allow maximal ﬂexibility in the data model [11].Data quality, missing data and imputation
Data found in the clinical data sources were assumed to be cor-
rect and complete. No review or update of clinical sources was per-
formed. The underlying hypothesis is that the amount of data will
compensate sufﬁciently for any data quality issues that may or
may not be present. The quality of the data extraction process
was checked via spot crosschecks with the source systems andwith a spreadsheet from previous work that contained data manu-
ally collected on a subset of patients. No errors were found.
Clinical data sources often have missing data elements. In this
study these were imputed using a Bayesian network. Such a net-
work can leverage existing data to infer missing data (e.g., a N0
stage patient is likely to have zero positive lymph nodes on a PET
scan) [12]. This network was learned from the training cohort
(Hugin Researcher, Hugin Expert, Aalborg, Denmark) and used to
impute ECOG performance status, FEV1 and PLNS.Estimating DSS performance and statistical considerations
The DSS was implemented and validated in Matlab (Mathworks,
Natick, MA, USA). After imputation of missing data elements, the
predicted 2 year-OS in the clinical cohort was comparedwith actual
outcome. The predictive performance of the DSS was assessed in
terms of discrimination and calibration [13]. Discrimination
between those reaching and those not reaching two year survival
was tested using the area-under-the-curve (AUC) of the receiver
operating characteristic curve and the Matthews correlation coefﬁ-
cient at 50% predicted probability of survival. From previous work,
cut-offs in terms of survival probability were deﬁned to divide the
training cohort into three prognostic groups (poor, medium and
good prognosis consisting of 25%, 50% and 25% of patients respec-
tively). The same cut-offs were applied to the clinical cohort and
the difference in survival of the three prognostic groups was tested
using Kaplan–Meier survival curves and a logrank test. Calibration
refers to the agreement between observed outcomes and predic-
tions and was assessed using a calibration plot with the same three
prognostic groups.[14] A signiﬁcance level of 0.05 was used with a
Bonferroni–Holm correction for multiple comparisons between the
two cohorts and between multiple survival curves.Role of the funding source
All funding sources were public and had no role in any of the
following areas: study design; collection, analysis, and interpreta-
tion of data; writing of the report; decision to submit the paper for
publication.
Results
Data extraction & imputation
In total 3919 patients (1995–2013) were identiﬁed as lung can-
cer patients of which 1301 had known stage I–IIIB NSCLC with 419
known to have received radical radiotherapy (>4500 cGy). Ulti-
mately 159 patientswere eligible for inclusion in the clinical cohort.
In Fig. 1 a diagram is givenwhich shows the reasons for exclusion of
patients. Since tumor volume was only recorded after the introduc-
tion of 3D treatment planning and 2 year-OS had to be known, the
clinical cohort only included patients treated between September
2002 and August 2011. The characteristics of the clinical and train-
ing cohort are given in Table 1. The clinical cohort had statistically
signiﬁcant larger tumor volumes. Staging and lung function where
somewhat different compared to the training cohort, but these did
not reach statistical signiﬁcance. The clinical cohort also had signif-
icantmissing data for PLNS (100%missing) and FEV1 (60%). Interest-
ingly the Bayesian network imputed a worse general condition
(poorer ECOG and lower FEV1) for patients with lower stage disease
than for patients with higher stage disease (not shown).DSS performance
The AUC of the DSS in the clinical cohort was 0.69, which is
lower than the AUC found in the training cohort (AUC 0.75). The
Table 1
Patient characteristics.
Training cohort Clinical cohort
Site Netherlands Australia
# Patients 322 159
Age (years) Mean ± SD 69 ± 10 68 ± 11 p = NS
Gender
Male 249 (77%) 113 (71%) p = NS
Female 73 (23%) 46 (29%) p = NS
Stage
I 73 (23%) 26 (16%) p = NS
II 29 (9%) 26 (16%) p = NS
IIIA 81 (25%) 62 (39%) p = NS
IIIB 134 (42%) 45 (28%) p = NS
Missing 5 (2%) 0a (0%)
ECOG
0 94 (29%) 49 (31%) p = NS
1 169 (53%) 72 (45%) p = NS
P2 52 (16%) 13 (8%) p = NS
Missing 7 (2%) 25 (16%)
FEV1 (%)
Mean ± SD 70 ± 24 77 ± 20 p = NS
Missing 48 (15%) 95 (60%)
Tumor volume (cc)
Mean ± SD 106 ± 113 161 ± 147 p < 0.001
Median 77 106
Missing 36 (11%) 0a (0%)
PLNS
0 143 (44%) N/A
1 59 (18%) N/A
2 44 (14%) N/A
3 31 (10%) N/A
P4 30 (9%) N/A
Missing 15 (5%) 159b (100%)
2 year OS
Yes 103 (32%) 58 (36%) p = NS
No 219 (68%) 101 (64%) p = NS
Missing 0 (0%) 0a (0%)
ECOG: Performance status as deﬁned by Eastern Cooperative Oncology Group; FEV1: forced expiratory volume in 1 s; tumor volume = gross tumor volume of the primary
tumor and involved nodes; PLNS = number of positive lymph node stations on a PET scan; 2 year OS = two year overall survival after the start of radiotherapy. p-Values
corrected for multiple comparisons using Bonferroni–Holm.
a Patients with missing data were excluded from the clinical cohort.
b Is not recorded in routine clinical practice in the Australian center.
Fig. 1. Diagram showing the reduction in the number of eligible patients when applying the inclusion and exclusion criteria (histology, stage and radical RT) and when
excluding patients with missing data elements (2 year survival and tumor volume). A total of 3919 had a diagnosis of lung cancer in the source system, of these 159 were
eligible for inclusion in the clinical cohort. Green indicates patients meeting the inclusion criteria or having a known data element, red patients were excluded because of an
exclusion criteria. Gray indicates patients in which a criteria or data element was unknown. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
A. Dekker et al. / Radiotherapy and Oncology 113 (2014) 47–53 49receiver operating curve showed that the DSS performed better in
the clinical cohort at higher operating points (medium-good prog-
nosis,) than at lower operating points (poor prognosis). The Mat-
thews correlation coefﬁcient at 50% predicted survival was 0.35
with false negatives the main limit of the model at this operating
point.
TheKaplan–Meier curves for the good,mediumandpoor progno-
sis group are given in Fig. 2(top). This shows that a good prognosis
group was successfully identiﬁed (2 year-OS 69%, p < 0.001), but
that the survivaldifferencebetween themediumandpoorprognosisgroup (2 year-OS 30% and 27%, p = NS) could not be reproduced in
the clinical cohort. More than half of the good prognosis group con-
sisted of stage IIIA–IIIB patients. Compared to the training cohort,
the clinical cohort had fewer patients in the poor prognosis group
(25% vs. 12%).
Fig. 2(bottom) shows that TNM stage I–II and IIIA–IIIB could
also discriminate between a good (2 year OS 47%) and poor prog-
nosis group (2 year OS 36%), but that discrimination was not as
good as the DSS and did not reach statistical signiﬁcance
(p = 0.12).
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Fig. 3. Calibration plot of the DSS for the clinical cohort using three prognosis
groups. Each point represents the predicted and observed probability for the group.
The error bar is the 95% conﬁdence interval. On the axis the number of survivors
and non-survivors are shown per 2% interval predicted probability. The calibration
curve of the medium prognosis group is not different from the ideal curve, in the
good and poor prognosis group a higher than predicted survival is observed.
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Fig. 2. Top: Kaplan–Meier curves of the clinical cohort (including censored survival
data so numbers are higher than Table 1) stratiﬁed by good, medium and poor
prognostic score from the training cohort [9]. The two year overall survival for these
three groups were 69%, 27% and 30% respectively. The separation between the good
and medium/bad prognosis group was highly signiﬁcant (p < 0.001). More than half
of the good prognosis group comprised advanced stage patients (20 stage I, 10 stage
II, 27 stage IIIA and 10 stage IIIB patients). Unlike what was found in previous work,
the medium and poor prognosis group of the clinical cohort did not show a
signiﬁcant difference in survival. Bottom: Kaplan–Meier curves of the clinical
cohort including censored survival data stratiﬁed by TNM stage. The difference
between stage I–II and stage IIIA–IIIB did not reach signiﬁcance (2 year-OS 47% vs.
36%, p = 0.12). p-Values corrected for multiple comparisons using Bonferroni–Holm.
50 Rapid learning in practiceThe calibration plot is given in Fig. 3. The calibration was not
different from ideal in the medium prognosis group, but survival
was higher than predicted in the poor and good prognosis groups.
In Fig. 4 the Kaplan–Meier survival curves are given of patients
treated to a radical dose vs. a non-radical dose for the good and
poor prognosis groups. In both groups the patients receiving aradical radiation dose are seen to have a better survival than those
not receiving a radical dose. This effect is more pronounced in the
good prognosis group than in the poor prognosis group.Discussion
Rapid learning has been proposed as a framework whereby
‘‘routinely collected real-time clinical data drive the process of sci-
entiﬁc discovery, which becomes a natural outgrowth of patient
care.’’ [8,15]. In this study, we have demonstrated a practical appli-
cation of these ideas. We deployed a rapid leaning environment in
which clinical data were extracted and used to validate DSS, itself
learned on clinical data from another center in another country.
We believe that achieving interoperability and leveraging data
from many centers will be necessary to achieve sufﬁcient data vol-
ume and variety for valuable knowledge extraction.
The Achilles heel of rapid learning is data quality. Unlike data
from prospective trials, clinical data have errors, bias and are often
missing. This might lead to a ‘‘garbage in garbage out’’ qualiﬁcation
of the knowledge gained in rapid learning and might prevent one
from answering even the most basic questions. This study demon-
strates that the situation is not that bleak. Clinical data from
‘‘front-line’’ physicians are at least able to successfully validate a
DSS that can identify patients who are more likely to survive than
others (Fig. 2).
We used the data ‘as is’ without any effort to improve the qual-
ity of the data. This was deliberate, as it is not feasible to do this for
the large number of patients in a busy clinic. This can be viewed as
both a weakness and a strength of this study. The weakness is that
the underlying assumption of data gaps and errors being random
may not be valid. The strength is that this study shows that even
from routine clinical data with no quality checks there is some-
thing to learn.
Starting from close to 4000 patients, 419 patients were identi-
ﬁed who met the basic inclusion criteria and only 159 were
included in the clinical cohort, which is sobering given the mild cri-
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Fig. 4. Kaplan–Meier curves of the patients treated with a radical vs. those treated
with a non-radical radiation dose. Top: good prognosis patients. Bottom: poor
prognosis patients.
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is still much higher than the number of patients in clinical trials
which is estimated to be 2–3% in Australia [16]. Fig. 1 shows that
besides the histology and staging distribution, both of which were
in line with expected levels [2], only a minority of patients with
non-metastatic disease were treated with a radical dose. Such
insights and the ability to detect variations in local practice are
an important feature of a rapid learning environment.
Missing data led to a large reduction in the number of eligible
patients as well as required imputation in the eligible patients
(Table 1). A relatively easy way to avoid missing data is the use
of naming conventions [17]. Other data elements such as FEV1,
ECOG status and PLNS are often implicitly known based on the
available free text information, but signiﬁcant extra time isrequired to document these data in a structured manner. For these
novel data capture or data transfer methods may be considered.
Some of these missing data are unavoidable due to patients treated
before the era of CT simulation or too recently for the outcome.
These reasons are clearly time dependent which raises the concern
that, due to the inevitable correlation of time with practice, this
exclusion is biased. There is some evidence that this is true. The
clinical cohort contained mostly patients from 2006 to 2011 as ear-
lier patients had often tumor volumemissing and later patients did
not have enough follow-up. In a validation analysis (not shown)
these later patients (2011–2013) were more often stage I patients
and less often stage IIIB patients perhaps indicating early diagnoses
and/or other changes in practice over time. Another possibility of
bias is the staging method. As the training cohort came from
2002 to 2006 and the clinical cohort primarily from 2006 to
2011 and they came from different institutes it cannot be excluded
that the more recent clinical cohort was differently and more cor-
rectly staged due to more modern staging methods and/or that the
institutes used different staging methods with one of the two per-
haps superior. As an example, Table 1 shows that the training
cohort had 42% stage IIIB patients versus 28% in the clinical cohort.
It cannot be excluded that in the training cohort inferior staging
methods where used and that part of these stage IIIB patients are
in fact stage IV patients that were incorrectly staged. There are
no straightforward answers to the problem of biased and biased-
missing data. But having more patients from a wide range of eras
and institutions in combination with domain expertise will help
in detecting bias. Bayesian methods are probably the best way of
modeling bias [18] and, for instance, can be used to model the
probability that the staging is correct depending on the staging
method used.
A method for imputation is needed as missing data are unavoid-
able. In previous work we showed that Bayesian networks are
excellent to handle missing data [12]. The observation that the
Bayesian network imputed a better general condition (low ECOG
and high FEV1) for higher stage patients may be explained by the
selection of lower stage patients in good general condition for sur-
gery. This may also explain that stage is not a very good predictor
of survival in inoperable patients as was observed previously [19]
and can also be seen in Fig. 2(bottom). This point is further empha-
sized by the observation that most patients in the good prognosis
group were stage IIIA–IIIB patients. Although it seems better than
mean imputation, the imputation of the Bayesian Network is still
far from perfect. In a validation analysis (results not shown) the
imputed ECOG status and FEV1 were compared to patients with
observed ECOG and FEV1. As it is based on the training cohort,
the Bayesian Network has a strong preference for the most com-
mon ECOG status (ECOG 1) of the training cohort and predicts a
low FEV1 in stage I patients which is not observed in the clinical
cohort. In future work learning better and more extensive net-
works based on more patients may make this imputation more
generalizable and better.
We applied a DSS that was learned from a completely indepen-
dent training cohort and can predict survival in non-small lung
cancer patients. The DSS had a reasonable discriminatory perfor-
mance in the clinical cohort and was able to identify patients with
a good prognosis but could not discriminate between a medium
and poor prognosis. The observed AUC (0.69) is better than physi-
cian predicted outcomes (AUC 0.56) as was recently shown in a
prospective study [20].
The cut-off for radical radiation in this study was taken as 45 Gy
based on the idea that such a dose was intended to be radical at the
time it was given. However one could question if a different cut-off
such as 60 Gy, which currently has the highest level of evidence,
would not have been better. To check this, a validation analysis
(not shown) was done after including only patients with 60 Gy or
52 Rapid learning in practicemore in the clinical cohort. This did not change any of the conclu-
sions which might be a result of the rather ﬂat dose–response
curve if one assumes that a biological equivalent dose of 70 Gy is
needed to control 50% of the tumor [21] and that a dose of 60 Gy
in once-daily fractions has a biological equivalence of less than
50 Gy.
In the calibration analysis, we showed that patients in both the
good and poor prognosis survived longer than predicted (Fig. 3).
Possible explanations for the limited performance of the DSS are
that (a) clinical practice at the Australian centers is different from
the Netherlands in that patients with comorbidities and subopti-
mal general condition were more likely to be treated with pallia-
tive radiotherapy (Fig. 1) and (b) there are confounding features
not included in the model at the moment due to the limited train-
ing set (e.g., concurrent chemotherapy, details of palliative care)
which have a positive inﬂuence on survival. Including the Austra-
lian cohort in the training set would not only allow the model to
learn from these patients (e.g., to model the effect of radical vs.
non-radical dose) but also allowmore features to be included with-
out the risk of overﬁtting due to the increased size of the training
set. But the addition of the Australian cohort to the training cohort
to learn an updated DSS would also require another external cohort
for its validation. Such a rapid learning network that allows addi-
tion of diverse datasets from centers worldwide to learn new,
improve existing and validate DSS is the subject of ongoing
research.
The clinical relevance of this work lies in the individualization
of therapy. From a guideline perspective the inoperable, non-met-
astatic NSCLC population is homogenous with concurrent chemo-
radiation as its preferred treatment. However many patients are
not meeting the highly selective criteria for clinical trials from
which guidelines are derived. The patient may not be considered
ﬁt enough for concurrent chemoradiation or a radical radiotherapy
dose may be considered too toxic due to the tumor size or location.
A DSS learned and validated using rapid learning approaches such
as presented here, support these clinical decisions objectively and
can be used to direct resources to the patients that might beneﬁt
most from them. The good-prognosis patients in whom currently
a non-radical dose is given, can be expected to especially beneﬁt
from advanced technologies such as intensity modulated and
image guided radiotherapy in order to feasibly treat these patients
with a radical dose. The comparison given in Figs. 3 and 4 (top) also
gives some indication of the expected and testable survival beneﬁt:
The model predicted two year overall survival is about 60% for
good prognosis patients if they are given a radical dose (Fig. 3)
while the clinical cohort suggests that a non-radical dose leads to
a survival of only about 20% in good prognosis patients (Fig. 4
(top)).
Vice versa, one can question if poor prognosis patients should
receive long course radiotherapy to a radical dose as the DSS does
not predict a survival beneﬁt compared to palliative radiotherapy
(Figs. 3 and 4 (bottom)). Although rapid learning thus give guid-
ance in these often difﬁcult decisions, the use of a DSS and result-
ing practice changes should be rigorously and prospectively tested
to validate that these practice changes indeed result in better out-
comes. This prospective validation is the subject of future work
where in a randomized seamless Phase II–III design patients will
be treated with or without the help of a DSS predicting survival
(and toxicity based on previous work) with the primary Phase II
endpoint being a change in practice between the two arms and
Phase III the primary endpoint overall survival which, if successful,
would lead to level I evidence for the use of a DSS in these patients.
The previous insights on the clinical relevance and the limita-
tions of the DSS have been made possible by the inclusion of data
from a site that treats patients differently than the cohort from
which the DSS was learned. This is a general characteristic of rapidlearning. Only by combining diverse datasets from a wide variety
of patient populations and health care practices will the size and
diversity of the data be sufﬁcient to perform clinically relevant
rapid learning. In our rapid learning vision, new data from addi-
tional sources and/or new patients are used to continuously
improve and validate knowledge and change practice.
In future work the rapid learning environment described in this
report, will be deployed at more hospitals to improve the DSS in
the following manner: ﬁrst this work clearly shows the DSS needs
a better accuracy and generalizability especially in patients with a
poor prognosis. Second, to increase its clinical relevance, the DSS
should predict both survival and quality-of-life affecting toxicities
of the various treatments. Third, the DSS should be able to handle
missing data rather than relying on imputation during pre-pro-
cessing, as was done in the present study. Given these require-
ments, Bayesian networks seem to be the ideal machine learning
approach for this type of work [12,22] and learning and validating
these is the subject of future work.
Finally the efforts described in this report need to be linked to
other rapid learning initiatives, such as CancerLinQ of the American
Society of Clinical Oncology, to achieve a true multi-disciplinary
rapid learning environment [23].Conﬂicts of interest statement
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